Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study of Bemarituzumab and Chemotherapy for Patients with Advanced Stomach or Gastroesophageal Cancer with FGFR2b Overexpression

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer known as Advanced Gastric or Gastroesophageal Junction Cancer that shows a specific characteristic called FGFR2b overexpression. The study is testing a new treatment called Bemarituzumab, also known by its code name AMG 552, in combination with a group of chemotherapy drugs. These chemotherapy drugs include Oxaliplatin, Folinic Acid, and Fluorouracil. The trial will compare the effects of this combination against a placebo combined with the same chemotherapy drugs.

The purpose of the study is to see if the combination of Bemarituzumab and chemotherapy can improve the overall survival of patients with this type of cancer. Participants in the study will receive either the new treatment or the placebo, and their health will be monitored over time to assess the treatment's effectiveness. The study will involve regular check-ups and assessments to track the progress of the disease and any side effects from the treatment.

Throughout the study, participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The trial aims to provide valuable information on whether this new treatment can offer better outcomes for patients with Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression. The study is expected to continue until 2025, allowing researchers to gather comprehensive data on the treatment's impact.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, participation begins with the administration of informed consent. This ensures understanding of the study's purpose and procedures.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to confirm eligibility. This includes a review of medical history and a physical examination.

    Tests are performed to ensure adequate organ function and to confirm the presence of FGFR2b overexpression in the tumor.

  3. Step 3

    Randomization

    Participants are randomly assigned to one of two groups: one receiving bemarituzumab plus chemotherapy, and the other receiving a placebo plus chemotherapy.

  4. Step 4

    Treatment administration

    Treatment involves the administration of bemarituzumab or placebo, along with chemotherapy drugs oxaliplatin, folinic acid, and fluorouracil.

    All medications are given through intravenous infusion. The specific dosage and frequency are determined by the study protocol.

  5. Step 5

    Ongoing monitoring

    Regular monitoring is conducted to assess the response to treatment and to identify any side effects.

    This includes physical examinations, blood tests, and imaging studies as needed.

  6. Step 6

    Completion of treatment

    Treatment continues until disease progression, unacceptable side effects, or completion of the study period.

    Participants are followed up to assess overall survival and response to treatment.

  7. Step 7

    Final assessment

    A final assessment is conducted to evaluate the overall outcome of the treatment.

    This includes a review of any changes in health status and quality of life.

Who can join the trial?

9 criteria

  • The person must agree to participate and sign a consent form before any study activities begin.
  • The person must be at least 18 years old or the legal adult age in their country, whichever is older.
  • The person must have a specific type of stomach cancer or cancer where the stomach meets the esophagus, confirmed by a tissue sample. This cancer cannot be cured with surgery.
  • The cancer must be advanced, meaning it cannot be removed by surgery, has spread locally, or has spread to other parts of the body.
  • The cancer must show a certain level of a protein called **FGFR2b** in at least 10% of the tumor cells, determined by a special test.
  • The person must be able to perform daily activities with little or no assistance, as measured by a scale called the **ECOG performance status**, which should be 0 or 1.
  • The person must have organs that are working well enough, with specific blood counts and liver and kidney function levels within acceptable ranges.
  • The person must have cancer that can be measured or evaluated using a standard method called **RECIST v1.1**.
  • The person must not have any medical reasons that would prevent them from receiving a type of chemotherapy called **mFOLFOX6**.

Who cannot join the trial?

4 criteria

  • Patients who have already received treatment for their **advanced stomach cancer** or **cancer at the junction of the stomach and esophagus** cannot participate. **Advanced** means the cancer has spread beyond its original location.
  • Patients whose cancer does not show a specific characteristic called **FGFR2b overexpression** are not eligible. **FGFR2b overexpression** means that the cancer cells have a high amount of a certain protein on their surface.
  • Patients who are not within the specified age range for the study cannot participate. The study has specific age requirements.
  • Patients who are part of a vulnerable population, which means they might need special protection or care, are not eligible.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Bemarituzumab

    is a medication being studied for its potential to treat advanced gastric or gastroesophageal junction cancer. It works by targeting a specific protein called FGFR2b, which is found in higher amounts in some cancer cells. By blocking this protein, bemarituzumab may help slow down or stop the growth of cancer cells.

  • Chemotherapy

    in this trial refers to a combination of cancer-fighting drugs used to kill or stop the growth of cancer cells. The specific regimen used in this study is called mFOLFOX6, which includes a mix of different chemotherapy drugs. These drugs work together to attack cancer cells in various ways, aiming to improve the patient's overall survival.

What is already known about the treatment

Bemarituzumab – Bemarituzumab is administered intravenously and is currently being studied in clinical trials for its effectiveness in treating advanced gastric or gastroesophageal junction cancer with FGFR2b overexpression. It is in the investigational stage and not yet widely available in medical practice. The main therapeutic indication is for patients with previously untreated advanced forms of these cancers. Bemarituzumab works by targeting and inhibiting the FGFR2b protein, which is involved in cancer cell growth and survival. It is classified as a monoclonal antibody, a type of targeted cancer therapy.

Investigated diseases

Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression – This is a type of cancer that occurs in the stomach or the area where the stomach meets the esophagus. It is characterized by the overexpression of the FGFR2b protein, which can promote cancer cell growth. The disease typically progresses as cancer cells multiply and spread to nearby tissues and potentially to other parts of the body. Symptoms may include difficulty swallowing, weight loss, and stomach pain. As the cancer advances, it can lead to more severe symptoms and complications. The progression of the disease can vary based on individual factors and the specific characteristics of the cancer.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-505457-40-00Protocol code20210096Estimated enrolment500 patientsSponsorAmgen Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).